Russian Heart Failure Journal 2008year Pathophysiological processes in kidneys of patients with CHF


To access this material please log in or register

Register Authorize
2008/

Pathophysiological processes in kidneys of patients with CHF

Arutyunov G. P.

Keywords:

DOI:

    1.    Brenner BM, Rector FC Jr. The kidney. 4th ed. Philadelphia. W. B. Saunders Co 1991.
    2.    Seldin DW, Giebisch G. The kidney: Physiology and Pathophysiology. 2nd ed. NY Raven Press 1992.
    3.    Windhager EE. Renal Physiology In Handbook of Physiology, Section 8. NY. Oxford University Press 1992.
    4.    Kriz W, Bankir L. A standard nomenclature for structures of the kidney. The Renal Commission of the International Union of Physiological Sciences (IUPS). Kidney Int. 1988;33 (1):1–7.
    5.    Beeuwkes R 3rd. The vascular organization of the kidney. Annu Rev Physiol. 1980;42:531–542.
    6.    Morel F, Doucet A. Functional segmentation of the nephron. In Seldin D. W. 1992 «The kidney», chapter 31.
    7.    Sands JM, Kokko JP, Jacobson HR. Intrarenal heterogeneity vascular and tubular. In Seldin D. W. 1992 «The kidney», chapter 32.
    8.    Selcurt EE. The relation of renal blood flow to effective arterial pressure in the intact kidney of the dog. Am J Physiol. 1946;147:537‑P549.
    9.    Cassellas D, Moore LG. Autoregulation and tubuloglomerular feedback in juxtamedullary glomerular arterioles. Am J Physiol. 1990;258 (3 Pt 2): F660–669.
    10.    Sanchez-Ferrer CF, Roman RJ, Harder DR. Pressure-dependent contraction of rat juxtamedullary afferent arterioles. Circ Res. 1989 Apr;64 (4):790–798.
    11.    Ito S, Abe K. Tubuloglomerular feedback. Jpn Heart J. 1996;37 (2):153–163.
    12.    Schnermann J, Weihprecht H, Briggs JP. Inhibition of tubuloglomerular feedback during adenosine1 receptor blockade. Am J Physiol. 1990;258 (3 Pt 2): F553–561.
    13.    Greger R. Chloride transport in thick ascending limb, distal convolution and collecting duct. Annu Rev Physiol. 1988;50:111–122.
    14.    Dubinsky WP Jr. The physiology of epithelial chloride channels. Hosp Pract (Off Ed). 1989;24 (1):69–80, 82.
    15.    Culpepper RM. Na+-K+-2Cl- cotransport in the thick ascending limb of Henle. Hosp Pract (Off Ed). 1989 Jun 15;24 (6):217–221, 225–226, 231–233 passim.
    16.    Bugge JF, Stokke ES, Kiil F. Hemodynamics regulation of renal prostaglandin and renin release. Acta Physiol Scand. 1988;134 (2):235–245.
    17.    Jackson EK. Adenosine: a physiological brake on renin release. Annu Rev Pharmacol Toxicol. 1991;31:1–35.
    18.    Shnermann JS, Briggs JP. Functions of the juxtaglomerular apparatus: control of glomerular hemodynamics and renin secretion. In Seldin D. W. 1992 «The kidney», chapter 35.
    19.    Young DK, Marsh DJ. Pulse wave propagation in rat renal tubules: implications for GFR autoregulation. Am J Physiol. 1981;240 (5): F446–458.
    20.    Müller GA, Rodemann HP. Characterization of human renal fibroblasts in health and disease: I. Immunophenotyping of cultured tubular epithelial cells and fibroblasts derived fr om kidneys with histologically proven interstitial fibrosis. Am J  Kidney Dis. 1991;17 (6):680–683.
    21.    Рогов К. А., Кальмаева О. В. Клинико-морфологические параллели у больных ХСН различных функциональных классов. Журнал Сердечная Недостаточность. 2006;7 (1):29–31.
    22.    Mattana J, Singhal PC. Applied pressure modulates mesangial cell proliferation and matrix synthesis. Am J Hypertens. 1995;8 (11):1112–1120.
    23.    Moss NG, Colinders RE, Gottschalk CW. Neural control of renal function. In Windhager E. E. «Renal physiology» NY, Oxford University Press 1992, chapter 22.
    24.    Stein JH. Regulation of the renal circulation. Kidney Int. 1990;38 (4):571–576.
    25.    Fisher NDL, Allan DR, Gaboury GL et al. Intrarenal A-II formation in humans: evidence from renin inhibitions. Am J Hypertens 1995, 8, 152 (Abstract).
    26.    Yanagawa N, Capparelli AW, Jo OD et al. Production of angiotensinogen and renin-like activity by rabbit proximal tubular cells in culture. Kidney Int. 1991;39 (5):938–941.
    27.    Wang T, Wu XH, Zhang SL et al. Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells. Kidney Int. 1998;53 (2):312–319.
    28.    Davis JO. The control of renin release. Am J Med. 1973;55 (3):333–350.
    29.    Lorenz JN, Weihprecht H, Schermann J et al. Characterization of the macula densa stimulus for renin secretion. Am J Physiol. 1990;259 (1 Pt 2): F186–193.
    30.    Canaan-Kühl S, Ostendorf T, Zander K et al. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int. 1998;53 (5):1143–1151.
    31.    Mu JY, Hansson GC, Lundgren O. The small intestine, salt intake and arterial hypertension. Blood Press. 1995;4 (2):77–79.
    32.    Pares I, de la Sierra A, Coca A et al. Detection of a circulating inhibitor of the Na (+)-K (+)-Cl (-) cotransport system in plasma and urine after high salt intake. Am J Hypertens. 1995;8 (10 Pt 1):965–959.
    33.    Woods RL. Contribution of the kidney to metabolic clearance of atrial natriuretic peptide. Am J Physiol. 1988;255 (6 Pt 1): E934–941.
    34.    Schenker Y. Atrial natriuretic hormone. Effect on renal function and aldosterone secretion in sodium depletion. Am J Physiol. 1988;255 (6 Pt 2): R867–873.
    35.    Pichet R, Cantin M, Thibault G, Lavallée M. Hemodynamic and renal responses in physiological levels of ANF in conscious dog. Hypertension. 1989;14 (1):104–110.
    36.    Gaillard CA, Mizelle HL, Montani JP et al. Atrial natriuretic factor and blood pressure control: role of sodium and aldosterone. Am J Physiol. 1990;259 (5 Pt 2): R973–980.
    37.    Fenoy FJ, Quesada T, Garsi-Salom M et al. Hemodynamic effects of chronic infusion of rANP in renal hypertensive rats. Am J Physiol. 1989;256 (5 Pt 2): H1393–1398.
    38.    Mené P, Dunn MJ. Eicosanoids and control of mesangial cell contraction. Circ Res. 1988;62 (5):916–925.
    39.    Conrad K. P, Dunn M. J. Renal prostaglandins and other eicosanoids. In Windhager E. E. «Renal physiology» N. Y, Oxford University Press (1992), chapter 35.
    40.    Makino H, Hironaka K, Shikata K et al. Mesangial matrix act a mesangial channels to the juxtaglomerular zone. Nephron. 1994;66 (2):181–188.
    41.    Gabbai FB. The glomerular capillary membrane a passive or active structure. J Lab Clin Med. 1995;125 (4):419–420.
    42.    Maddox DA, Brenner BM. Glomerular ultrafiltration. In Brenner B. M. «The Kidney». W. B. Saunders CO 1991, chapter 6.
    43.    Maddox DA, Deen WM, Brenner BM. Glomerular filtration. In Windhager E. E. «Renal Physiology» N. Y, Oxford University Press, 1992, chapter 13.
    44.    Ulfendahl HR, Wolgast M. Renal circulation and lymphatics. In Seldin D. W. «The kidney» N. Y, Raven Press, 1992, chapter 30.
    45.    Shayman JA. Renal pathophysiology. Lippincott’s pathophysiology series. Philadelphia, 1996, chapter 8.
    46.    Breyer MD. Regulation of water and salt transport in collecting duct through calcium-dependent signaling mechanisms. Am J Physiol. 1991;260 (1 Pt 2): F1–11.
    47.    Stokes JB. Sodium and potassium transport by the collecting duct. Kidney Int. 1990;38 (4):679–686.
    48.    Wilcox CS, Baylis C, Wingo CS. Glomerular-tubular balance and proximal regulation. In Seldin D. W. «The kidney» N. Y, Raven Press, 1992, chapter 50.
    49.    Minuth WW, Steckelings U, Gross P. Methylation of cytosolic proteins may be a possible biochemical pathway of early aldosterone action in cultured renal collecting duct cells. Differentiation. 1987;36 (1):23–34.
    50.    Quinn SJ. Regulation of aldosterone secretion. Annu Rev Physiol. 1988;50:409–426.
    51.    Ebert TJ, Cowley AW, Skelton M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in men. J Clin Invest. 1986;77 (4):1136–1142.
    52.    Conzales-Campoy JM, Knox FJ. Integrated responses of the kidney to alterations in extracellular fluid volume. In Seldin D. M. «The kidney», N. Y, Raven Press, 1992, chapter 56.
    53.    Robertson GL. Regulation of vasopressin secretion. In Seldin D. W. «The kidney» N. Y, Raven Press, 1992, chapter 43.
    54.    Gellai M. Modulation of vasopressin antidiuretic action by renal alpha 2‑adrenoceptors. Am J Physiol. 1990 Jul;259 (1 Pt 2): F1–8.
    55.    Schafer JA, Chen L. Low Na+ diet inhibits Na+ and water transport response to vasopressin in rat cortical collecting duct. Kidney Int. 1998 Jul;54 (1):180–187.
    56.    Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102 (2):203–210.
    57.    Burnett JC, Costello-Boerrigter L, Boerrigter G, Alterations in the Kidney in Heart Failure: The Cardiorenal Axis in the Regulation of Sodium Homeostasis, in Heart Failure, Mann DL, Editor. 2004: Philadelphia. 279–289.
    58.    Cowburn PJ, Cleland JG, Coats AJ, Komajda M. Risk stratification in chronic heart failure. Eur Heart J. 1998;19 (5):696–710.
    59.    Parameshwar J, Keegan J, Sparrow J et al. Predictors of prognosis in severe chronic heart failure. Am Heart J. 1992;123 (2):421–426.
    60.    Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001;38 (7):1782–1787.
    61.    Fried LF, Shlipak MG, Crump G et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003;41 (8):1364–1372.
    62.    Packer M. Why do the kidney release renin in patients with congestive HF? A nephrocentric view of converting-enzyme inhibition. Eur Heart J. 1990;11 (Suppl D):44–52.
    63.    Madsen BK, Keller N, Christiansen E, Christensen NJ. Prognostic value of plasma catecholamines, plasma renin activity, and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: comparison with clinical evaluation, ejection fraction, and exercise capacity. J Card Fail. 1995;1 (3):207–216.
    64.    Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70 (4):479–487.
    65.    Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325 (21):1468–1475.
    66.    Hampton JR, Van Veldhuisen DJ, Kleber FX et al. Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME-II) Investigators. Lancet. 1997;349 (9057):971–977.
    67.    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16 (1):31–41.
    68.    Robertshaw M, Lai KN, Swaminathan R. Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. Br J Clin Pharmacol. 1989;28 (3):275–280.
    69.    Waller DG, Fleming JS, Ramsey B, Gray J. The accuracy of creatinine clearance with and without urine collection as a measure of glomerular filtration rate. Postgrad Med J. 1991;67 (783):42–46.
    70.    Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs. 1990;39 (Suppl 4):10–21.
    71.    Leithe ME, Margorien RD, Hermiller JB et al. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation. 1984;69 (1):57–64.
    72.    Dzau VJ. Renin-angiotensin system and renal circulation in clinical congestive heart failure. Kidney Int Suppl. 1987;20: S203–209.
    73.    Elsner D. Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function. Eur Heart J. 1995;16 (Suppl N):52–58.
    74.    Dries DL, Exner DV, Domanski MJ et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35 (3):681–689.
    75.    Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47 (10):1987–1996.
    76.    Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130 (6):461–470.
    77.    Cowie MR, Komajda M, Murray-Thomas T et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated HF: results of the prospective outcomes study in HF (POSH). Eur Heart J. 2006;27 (10):1216–1222.
    78.    Butler J, Forman DE, Abraham WT et al. Relationship between HF treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147 (2):331–338.
    79.    Smilde TM, Hillege HL, Navis G et al. Formulas estimating renal function give imprecise estimates in HF. J Am Coll Cardiol. 2005;45: 172A-177A.
    80.    O’Meara E, Chong KS, Gardner RS et al. The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. Eur J Heart Fail. 2006;8 (1):63–67.
    81.    Krumholz HM, Chen YT, Vaccarino V et al. Correlates and impact on outcomes of worsening renal function in patients > or = 65 years of age with heart failure. Am J Cardiol. 2000;85 (9):1110–1113.
    82.    Smith GL, Vaccarino V, Kosiborod M et al. Wosening renal function what is a clinically meaningful change in creatinine during hospitalization with HF. J Card Fail. 2003;9 (1):13–25.
    83.    Gottlieb SS, Abraham W, Butler J et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8 (3):136–141.
    84.    Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43 (1):61–67.
    85.    Erdmann E, Lechat P, Verkenne P et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 2001;3 (4):469–479.
    86.    Lucas DG Jr, Hendrick JW, Sample JA et al. Cardiorenal effects of A1‑receptor inhibition in an experimental model of HF. J Am Coll Surg. 2002;194 (5):603–609.
    87.    Gheorghiade M, Gattis WA, O’Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291 (16):1963–1971.
    88.    Colluci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343 (4):246–253.
    89.    Yamamoto K, Burnett JC Jr, Redfield MM. Effect of endogenouse natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997;273 (5 Pt 2): H2406–2414.
    90.    Brunner La Roca HP, Kaye DM, Woods RL et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with CHF as compared with healthy control subjects. J Am Coll Cardiol. 2001;37 (5):1221–1227.
    91.    Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287 (12):1531–1540.
    92.    Elkayam U, Akhter MW, Singh H et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2004;93 (2):237–240.
    93.    Cattaliotti A, Boerrighter G, Costello-Boerrihter LC et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004;109 (13):1680–1685.
    94.    Butler J, Emerman C, Peacock WF et al. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004;19 (2):391–399.
    95.    Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356 (9230):615–620.
    96.    Reilly RF, Ellison DH. Mammalian distal tubule: physiology, pathophysiology and molecular anatomy. Physiol Rev. 2000;80 (1):277–313.
    97.    Remuzzi G, Bertrani T. Pathophysiology of progressive nephropaties. N Engl J Med. 1998;339 (20):1448–1456.
    98.    Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Wh ere do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32 (5):853–906.
    99.    Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134 (8):629–636.
    100.    Seliger SL, Weiss NS, Gillen DL et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.. Kidney Int. 2002;61 (1):297–304
    101.    Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59 (1):260–269.
    102.    Kanwar YS, Liu ZZ, Kashihara N et al. Current status of the structural and functional basis of glomerular filtration and proteiuria. Semin Nephrol. 1991;11 (4):390–413.
    103.    Sano T, Kawamura T, Matsumae H et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care. 1994;17 (5):420–324.
    104.    Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2001;24 (Suppl 1): S33‑S43.
    105.    Gaber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dog. Kidney Int. 1994;46 (1):161–169.
    106.    Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7‑year follow-up study. Arch Intern Med. 1996;156 (3):286–289.
    107.    The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355 (9200):253–259.
    108.    Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310 (9):563–572.
    109.    Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Am J Hypertens. 1999;12 (12 Pt 3):195S-203S.
    110.    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160 (5):685–693.
    111.    Reardon LC, Macpherson DS, Reardon LC et al. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158 (1):26–32.
    112.    Murray MD, Deer MM, Ferguson JA et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111 (7):513–520.
    113.    Sica DA. Dose adjustment of drugs in kidney disease. In Bakris G. L. «The kidney and hypertension», Taylor and Francis Group 2004, chapter 9.
    114.    Sica DA, Gehr TW, Fernandez A. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease. Drug Saf. 2000;22 (5):350–360.

To access this material please log in or register

Register Authorize
Ru En